Cardio Diagnostics Holdings, Inc. (CDIO) vs NuCana PLC Sponsored ADR (NCNA)

Cardio Diagnostics Holdings, Inc. and NuCana PLC Sponsored ADR are both Biotechnology companies. Cardio Diagnostics Holdings, Inc. and NuCana PLC Sponsored ADR are of similar size ($5.7M and $5.7M). NuCana PLC Sponsored ADR has the higher net margin (0.00% vs −44,312.3%) and the lower return on invested capital (−1,130.2% vs −219.4%). Across the 13 metrics below, NuCana PLC Sponsored ADR leads on 7 and Cardio Diagnostics Holdings, Inc. on 6.

Valuation

Metric CDIO NCNA Biotechnology median
P/E n/m n/m 7.88
P/S 395.28 n/m 11.47
P/B 0.78 0.00 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 1.45 0.74
EV/Sales 12.63 n/m 10.73
Earnings yield (149.74%) (175,037.66%) (28.84%)
Free cash flow yield (100.92%) (131,687.13%) (23.03%)

Profitability

Metric CDIO NCNA Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (44,230.82%) 0.00% 0.00%
Net margin (44,312.33%) 0.00% 0.00%
Free cash flow margin (39,893.15%) 0.00% 0.00%
Return on equity (75.44%) (68.70%) (57.72%)
Return on assets (70.62%) (45.24%) (49.22%)
Return on invested capital (219.40%) (1,130.23%) 0.00%

Growth

Metric CDIO NCNA Biotechnology median
Revenue growth (TTM) (25.13%) — 5.64%
EPS growth (last fiscal year) 60.15% 98.96% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CDIO NCNA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 17.15 4.73 4.73
Net debt to EBITDA 0.84 1.23 0.96

Dividend

Metric CDIO NCNA Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric CDIO NCNA Biotechnology median
Market cap 5.65m 5.69m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack